Keyword: Gavi

Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.

Here's some other vaccine news of note for the week.

Here is some other vaccine news of note for the week.

Gavi's vaccine initiative will have saved 20 million lives and $350 billion in healthcare costs by 2020, a recent study found.

Congolese officials have given initial approval to the use of Merck’s as-yet-unlicensed Ebola shot to combat a local outbreak.

A rotavirus vaccine candidate showed better efficacy than Merck’s and GlaxoSmithKline’s approved vaccines in a late-stage trial.

In a deal that could save millions of lives, the United Nations Children’s Fund has reached an unprecedented agreement with six manufacturers that slashes the price of pentavalent vaccine to half what the agency currently pays.

Pfizer’s blockbuster vaccine Prevenar 13 will soon get a boost in a host of international markets. The shot won WHO backing in a new, easier-to-store formulation Tuesday, enabling increased access in poor countries by reducing costs--though pricing controversy hasn’t escaped the franchise in recent days.

Last July, WHO recommended that GlaxoSmithKline’s malaria vaccine Mosquirix be examined in pilot programs before introduction through large immunization campaigns. Now, international vaccine alliance Gavi is stepping in with conditional funding to help the upcoming real-world programs get underway.